AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30391169
Drug: Rupatadine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rupatadine 20 mg
Trial: 17478385
Drug: Rupatadine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rupatadine 10 mg and 20 mg
Trial: 17478385
Drug: Rupatadine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rupatadine 5 mg
Trial: 27492833
Drug: Aclidinium/formoterol 400/12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclidinium/formoterol 400/12 µg twice-daily
Trial: 27492833
Drug: Salmeterol/fluticasone 50/500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/fluticasone 50/500 µg twice-daily
Trial: 15462115
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (symptomatic treatment)
Trial: 16638030
Drug: Subcutaneous sterile
RxNorm normalized name: Steril-Eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous sterile water injection (0.5 mL)
Trial: 12785471
Drug: CBASP (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBASP (both alone and with medication)
Trial: 9008516
Drug: High plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High plasma valproate group (80 to 150 micrograms/mL)
Trial: 9008516
Drug: Low plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low plasma valproate group (25 to 50 micrograms/mL)
Trial: 8474315
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) 24 IU
Trial: 25038306
Drug: Intensive intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive intervention (LDL-C target <100 mg/dL, switching ART if needed, low-dose aspirin)
Trial: 25038306
Drug: Standard intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intervention (LDL-C target <130 mg/dL)
Trial: 23226979
Drug: Oral hyaluronic
RxNorm normalized name: hyaluronate Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hyaluronic acid (HA) 200 mg once a day for 12 months
Trial: 10189602
Drug: Sertraline (50-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50-150 mg)
Trial: 28935140
Drug: d-Allulose (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-Allulose (5 g)
Trial: 28935140
Drug: Aspartame (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame (10 mg)
Trial: 11736893
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro cytotoxicity model using HaCaT cells with various irritants (100 µL of 20 mmol L(‐1) aqueous solution)
Trial: 11736893
Drug: In vivo
RxNorm normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vivo irritation potential in humans after 24-hour application of the same compounds
Trial: 3147905
Drug: Cholestyramine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine (3 x 12 g daily for 4 weeks)
Trial: 3147905
Drug: Cholestyramine (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine (acute and chronic administration)
Trial: 28425029
Drug: AAFP 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAFP 125 mg, 500 mg, 625 mg
Trial: 30340765
Drug: Rivaroxaban 2.5
RxNorm normalized name: rivaroxaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 2.5 mg BID
Trial: 30340765
Drug: Rivaroxaban 5
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 5 mg BID
Trial: 25318481
Drug: Rivaroxaban (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (both doses combined)
Trial: 18926940
Drug: Alkaline mineral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkaline mineral water (water B) rich in bicarbonate (per litre: 547 mg Ca, 2172 mg HCO(3)(‐), 9 mg SO(4)(‐), PRAL ‐11.2 mEq)
Trial: 18926940
Drug: Acid calcium-rich
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acid calcium-rich water (water A) (per litre: 520 mg Ca, 291 mg HCO(3)(‐), 1160 mg SO(4)(‐), PRAL +9.2 mEq)
Trial: 28837210
Drug: Extended anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended anticoagulation with vitamin K antagonists
Trial: 23708468
Drug: Standard psychosocial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard psychosocial treatment
Trial: 21592879
Drug: Amlodipine/valsartan 10/320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/valsartan 10/320 mg
Trial: 12745039
Drug: Acetaminophen (ACET)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (ACET) 1000 mg
Trial: 8623187
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) - enoxaparin 40 mg/day
Trial: 3006619
Drug: Enalapril (EN)
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril (EN) 20 mg once-a-day
Trial: 29757924
Drug: Ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusion (40 μg kg min over 5 min followed by 2.5 μg kg min)
Trial: 29757924
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline infusion (control group)
Trial: 24287940
Drug: DEP 75
RxNorm normalized name: Endep 75 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEP 75 mg
Trial: 24287940
Drug: MZD 2
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MZD 2 mg
Trial: 24287940
Drug: SIB 15
RxNorm normalized name: duvelisib 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIB 15 mg
Trial: 22408266
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of antidepressant treatment (68 patients)
Trial: 17728419
Drug: Adjunctive antidepressant
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive antidepressant use
Trial: 12453326
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) 425 mg/m2 with low-dose folinic acid (FA) 20 mg/m2, administered as a rapid bolus intravenous injection for 5 days every 4-5 weeks
Trial: 12453326
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) with low-dose folinic acid (FA)
Trial: 10445530
Drug: Erythromycin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (3 mg/kg) administered intravenously over 15 min before consumption of 300 g minced beef and 150 ml water.
Trial: 7556858
Drug: Slow injection
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow injection of local anesthetic into one side of the cervix
Trial: 9673264
Drug: Acellular vaccine
RxNorm normalized name: PERTUSSIS VACCINE,ACELLULAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular vaccine
Trial: 7677415
Drug: Whole cell
RxNorm normalized name: pertussis, whole cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole cell vaccine
Trial: 2300411
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of acellular vaccine
Trial: 30465917
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate supplementation (1500 mg Ca/d)
Trial: 23498899
Drug: Instant coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instant coffee containing 3 mg of caffeine/kg body weight
Trial: 23498899
Drug: Instant coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instant coffee containing 6 mg of caffeine/kg body weight
Trial: 19124484
Drug: Coexpression of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coexpression of alpha6beta4 integrin and Net1 in hormone receptor-positive tumors
Trial: 17475318
Drug: Other sources
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other sources (e.g., word of mouth)
Trial: 15127079
Drug: Mifepristone (RU-486)
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mifepristone (RU-486) 600 mg/day
Trial: 28388932
Drug: Sodium benzoate
RxNorm normalized name: Sodium Benzoate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium benzoate (1000 mg, 500 mg twice daily for 12 weeks)
Trial: 24282343
Drug: Bridging treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bridging treatments (transarterial chemoembolization, radiofrequency ablation, surgical resection)
Trial: 24282343
Drug: Bridging treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bridging treatments
Trial: 24282343
Drug: Downstaging treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Downstaging treatments
Trial: 20883846
Drug: Warm Water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm Water Infusion (WWI)
Trial: 18413618
Drug: 90-microL testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 90-microL testosterone metered-dose transdermal spray
Trial: 15899748
Drug: 20-minute self-administered
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-minute self-administered intervention with normative feedback and goal setting
Trial: 10343191
Drug: Oral medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral medroxyprogesterone acetate 1,200 mg (arm I)
Trial: 10343191
Drug: Oral medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral medroxyprogesterone acetate 600 mg (arm II)
Trial: 10343191
Drug: Oral medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral medroxyprogesterone acetate (both arms)
Trial: 8745317
Drug: Recombinant interferon‐alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interferon‐alpha (rIFN) treatment
Trial: 30712963
Drug: Intraperitoneal chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal chemotherapy after complete or optimal primary surgery
Trial: 21868190
Drug: Suprascapular nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprascapular nerve block (10 mL of 1% ropivacaine)
Trial: 21868190
Drug: Subacromial infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subacromial infiltration of local anesthesia (20 mL of 1% ropivacaine)
Trial: 3033444
Drug: CE +
RxNorm normalized name: Multimineral/Multivitamin Oral Tablet [ACE + Z]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE + cyproterone acetate (CPA) 12.5 mg/day from day 1 to day 10
Trial: 3033444
Drug: Tibolone (ORG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone (ORG OD14) 2.5 mg/day
Trial: 3033444
Drug: Placebo, one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, one tablet/day
Trial: 10797866
Drug: SPE‐712‐1 oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPE‐712‐1 oral suspension 300 mg/15 mL
Trial: 10797866
Drug: Rotram tablets
DrugBank: Roxithromycin (DB00778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotram tablets 300 mg
Trial: 7720912
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized DHEA (50 mg/d)
Trial: 2116441
Drug: Calcium infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium infusion started 1 min after TRH (Group A)
Trial: 2116441
Drug: Calcium infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium infusion started 10 min after TRH (Group B)
Trial: 2116441
Drug: Calcium infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium infusion started 20 min after TRH (Group C)
Trial: 31938840
Drug: 4 cc
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 cc autologous muscle-derived cell (AMDC) injections
Trial: 31938840
Drug: 4 cc
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 cc placebo solution injections
Trial: 26645209
Drug: Lurasidone (40-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone (40-80 mg/d, flexibly dosed)
Trial: 25091659
Drug: Pertuzumab (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pertuzumab (in combination with trastuzumab and docetaxel)
Trial: 16158743
Drug: Kanefron H
RxNorm normalized name: oxymetazoline hydrochloride Nasal Spray [Anefrin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kanefron H (KH) after initial anti-inflammatory treatment
Trial: 16158743
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (spasmolytic and anti-inflammatory therapy)
Trial: 12665729
Drug: Computer-assisted instructional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-assisted instructional (CAI) game focusing on reducing environmental irritants/allergens and correct use of prescribed medications for 12 weeks
Trial: 10757465
Drug: Imidapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidapril (10 mg) administered in the morning (07:00)
Trial: 10757465
Drug: Imidapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidapril (10 mg) administered in the evening (18:00)
Trial: 8843225
Drug: Bivalent recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent recombinant baculovirus influenza A vaccine (rHA0)
Trial: 8843225
Drug: Monovalent recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent recombinant baculovirus influenza A vaccine (rHA0)
Trial: 8843225
Drug: Standard trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard trivalent inactivated vaccine (TIV)
Trial: 8843225
Drug: Increasing doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing doses of A/Texas rHA0 (15 micrograms)
Trial: 8843225
Drug: Increasing doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing doses of A/Texas rHA0 (45 micrograms)
Trial: 19953227
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg cortisol
Trial: 17876009
Drug: Self-administered stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered stress management training
Trial: 12065562
Drug: Professionally administered
RxNorm normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Professionally administered stress management training
Trial: 2203243
Drug: Bepridil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepridil (200 mg/day twice daily)
Trial: 2203243
Drug: CERM 4205
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CERM 4205 (200 mg/day twice daily)
Trial: 31093796
Drug: Oral screen
RxNorm normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral screen after MMF
Trial: 23269772
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (second cycle)
Trial: 7871360
Drug: Miconazole 2%
RxNorm normalized name: MICONAZOLE 200MG SUPP/MICONAZOLE 2% CREAM PAK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miconazole 2% gel applied four times daily for 2 weeks
Trial: 16906641
Drug: Zataria multiflora
RxNorm normalized name: Reynoutria multiflora root oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zataria multiflora 0.1% gel applied four times daily for 2 weeks
Trial: 10490157
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose fentanyl (15 microg x kg(‐1))
Trial: 10490157
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose fentanyl (1 microg x kg(‐1))
Trial: 8725888
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy with leuprolide plus flutamide
Trial: 1759789
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release verapamil (240 mg/24 h)
Trial: 1759789
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg, 50 mg/24 h)
Trial: 1759789
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sustained release verapamil + captopril
Trial: 26700279
Drug: Multidisciplinary Multistep
RxNorm normalized name: MultiStem
DrugBank: MultiStem (DB15742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary Multistep Medication Review (3MR)
Trial: 26076022
Drug: Donepezil hydrochloride
RxNorm normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil hydrochloride (DH) 5 mg/day
Trial: 19574961
Drug: Difference in
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Difference in BW before and after treatment between the two groups
Trial: 23265686
Drug: Rimonabant (cannabinoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimonabant (cannabinoid antagonist)
Trial: 16766329
Drug: M. vaccae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M. vaccae vaccine (two subcutaneous injections 3 months apart)
Trial: 8486881
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of quinine taken at bedtime
Trial: 21365028
Drug: Buccal plate
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal plate preservation (BPP)
Trial: 18390891
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (Benazepril and Valsartan)
Trial: 2015715
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment mentioned)
Trial: 11475742
Drug: Nitroglycerin 5
RxNorm normalized name: nitroglycerin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin 5 mg
Trial: 10556002
Drug: PAPU (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAPU (150 mg)
Trial: 773198
Drug: Methylprednisolone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (2 gm, approximately 30 mg/kg)
Trial: 29268598
Drug: Midazolam (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.05 mg/kg)
Trial: 29666026
Drug: Bevacizumab combined
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab combined with chemotherapy
Trial: 17382027
Drug: Small molecule
RxNorm normalized name: Small molecule melanocortin 4 receptor agonist
DrugBank: LB54640 (DB18331)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small molecule inhibitors targeting VEGF receptor and tyrosine kinase receptor combined with standard chemotherapy
Trial: 15126020
Drug: Nutritional supplements
RxNorm normalized name: nutritional supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplements (lemon-flavored cod liver oil and children's multivitamin-mineral with selenium)
Trial: 11641299
Drug: Saline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline and heparin
Trial: 11641299
Drug: Saline with
RxNorm normalized name: CVS Saline with Aloe Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline with intralipid and heparin
Trial: 2530998
Drug: mivacurium 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mivacurium 0.25 mg kg‐1
Trial: 444345
Drug: suxamethonium 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suxamethonium 1.0 mg kg‐1
Trial: 7640130
Drug: atracurium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atracurium 0.5 mg kg‐1
Trial: 2530998
Drug: mivacurium (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mivacurium (higher doses)
Trial: 1173736
Drug: Proprietary milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proprietary milk with lactase preparation
Trial: 31397943
Drug: bleselumab 50
RxNorm normalized name: Bleselumab
DrugBank: Bleselumab (DB15253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bleselumab 50 mg
Trial: 31397943
Drug: bleselumab 500
RxNorm normalized name: Bleselumab
DrugBank: Bleselumab (DB15253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bleselumab 500 mg
Trial: 29710295
Drug: Fosfomycin, single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosfomycin, single 3-g dose (n=258)
Trial: 26316344
Drug: tissue-type plasminogen
RxNorm normalized name: Tissue-type plasminogen activator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tissue-type plasminogen activator plus endovascular therapy (Solitaire device)
Trial: 23597719
Drug: RV3-BB rotavirus
RxNorm normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RV3-BB rotavirus vaccine (8.3×10(6)FFU/mL)